MLKL: Functions beyond serving as the Executioner of Necroptosis

Citations Over TimeTop 10% of 2021 papers

Abstract

Recently, necroptosis, as a programmed cell death pathway, has drawn much attention as it has been implicated in multiple pathologies, especially in the field of inflammatory diseases. Pseudokinase mixed lineage kinase domain-like protein (MLKL) serves as a terminal-known obligate effector in the process of necroptosis. To date, the majority of research on MLKL has focused on its role in necroptosis, and the prevailing view has been that the sole function of MLKL is to mediate necroptosis. However, increasing evidence indicates that MLKL can serve as a regulator of many diseases via its non-necroptotic functions. These functions of MLKL shed light on its functional complexity and diversity. In this review, we briefly introduce the current state of knowledge regarding the structure of MLKL, necroptosis signaling, as well as cross-linkages among necroptosis and other regulated cell death pathways, and we particularly highlight recent progress related to newly identified functions and inhibitors of MLKL. These discussions promote a better understanding of the role of MLKL in diseases, which will foster efforts to pharmacologically target this molecule in clinical treatments.

Related Papers

• → Necroptosis: Biochemical, Physiological and Pathological Aspects(2011)68 cited
• → Using Small Molecules to Dissect Non‐apoptotic Programmed Cell Death: Necroptosis, Ferroptosis, and Pyroptosis(2015)65 cited
• → Noncanonical cell death program independent of caspase activation cascade and necroptotic modules is elicited by loss of TGFβ-activated kinase 1(2017)11 cited
• → Shining light on cell death processes – a novel biosensor for necroptosis, a newly described cell death program(2014)13 cited
• → Necroptosis is involved in cardiac cell death induced by chemical ischemia(2008)2 cited